Compound Labs / United Kingdom
Nova Laboratories
Compounding pharmacy in Wigston, Leicester, England, United Kingdom. Listed, not endorsed.
Peptides Nova Laboratories names publicly
None named on its public pages.
Lists "peptides" as an aseptic capability for contract and clinical-trial work. No named products.
Licence and status, as stated
MHRA specials licence MS 13581 (aseptic small-volume liquids) and manufacturer's licence MIA(IMP) 13581.
Who it supplies
NHS hospitals and community pharmacies. Business to business only.
Sourcing and testing, as stated
Testing: In-house quality control and microbiology, as stated.
These are the pharmacy's own statements. No results are published.
The rules in the United Kingdom
UK compounding runs through two routes. One is an MHRA "specials" (MS) licence, which is GMP-inspected and lets the holder sell to other organisations. The other is the section 10 exemption for a registered pharmacy, overseen by the General Pharmaceutical Council (GPhC). Under both, the patient gets the product only through a prescriber.
Licensed semaglutide and tirzepatide exist in the UK, so a compounded copy is hard to justify. In April 2026 the MHRA opened an investigation into clinics marketing "experimental" peptide injections and said it disregards "research purposes" disclaimers. The GPhC has reminded pharmacy owners that they carry due-diligence responsibility for their suppliers. Licences on this page were checked against the MHRA register of specials manufacturers (September 2026) and GPhC records.